Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy

Soft-tissue sarcomas (STS), with over 100 different histologic subtypes, are rare tumors that account for 1% of all adult malignancies. Immune checkpoint inhibitors (ICIs) display certain benefits in some subtypes, especially in undifferentiated pleomorphic sarcoma (UPS), alveolar soft part sarcoma...

Full description

Bibliographic Details
Main Authors: Yong Li, Yihong Liu, Yanchun Qu, Xian Chen, Xin Qu, Yongsong Ye, Xiaohua Du, Ying Cheng, Mian Xu, Haibo Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Immunology
Subjects:
soft-tissue sarcomas
tumor mutational burden (TMB)
immune checkpoint inhibitors
anlotinib
toripalimab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.832593/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.832593/full

Similar Items